BIMZELX® Shows Promising Two-Year Results in Treating Hidradenitis Suppurativa at AAD 2025

BIMZELX®: A Game Changer in Hidradenitis Suppurativa Treatment

In a remarkable advancement for patients with moderate-to-severe hidradenitis suppurativa (HS), new data presented by UCB at the American Academy of Dermatology (AAD) 2025 highlights the significant efficacy of BIMZELX® (bimekizumab-bkzx) over two years of treatment. As the first approved therapy targeting both interleukin 17A (IL-17A) and interleukin 17F (IL-17F), BIMZELX® shows potential in not only alleviating symptoms but also in potentially eradicating debilitating draining tunnels, a common and painful result of this chronic skin condition.

Key Findings from the Study

Over 425 patients suffering from HS participated in the long-term BE HEARD trials, with striking results indicating that 55.7% of those with draining tunnels at baseline no longer experienced this symptom after two years on BIMZELX®. Draining tunnels, which can lead to extensive scarring and severe pain, represent a significant burden for patients, and this study provides hope for effective management and relief.

In addition to reducing draining tunnels, the study noted that 63.6% of participants reported either no skin pain or only mild discomfort at the two-year mark, a considerable improvement from only 10% at the study's outset. This reduction in pain is critical, as skin pain significantly influences the quality of life for HS patients.

Sustained and Broad Efficacy Across Patient Subgroups

UCB’s research further substantiates BIMZELX®'s effectiveness across various demographics, showing sustained improvements regardless of age, sex, or the severity and duration of the disease. Patients across all backgrounds experienced marked reductions in symptoms, underpinning the treatment's broad applicability.

Those who began treatment shortly after diagnosis fared even better, achieving high HiSCR90 and HiSCR100 response rates, suggesting that early intervention might play a pivotal role in treatment success. This emphasizes the necessity for prompt diagnosis and initiation of therapy for optimal outcomes.

Safety and Tolerability: A Positive Profile

The safety profile of BIMZELX® remained consistent, with no new significant safety concerns emerging in the second year. A majority of participants tolerated the treatment well, which is vital for patient compliance and long-term management of HS, a condition known for its painful and persistent symptoms.

UCB executives, including Fiona du Monceau, expressed their commitment to enhancing patient outcomes through ongoing research and development of new treatments. "These findings not only demonstrate the potential of BIMZELX® to address the immediate symptoms of HS but also to prevent long-term damage associated with draining tunnels," she emphasized.

Presentation of Results at AAD 2025

The comprehensive findings from the BE HEARD trials are set to be presented through multiple poster sessions during the AAD 2025 Annual Meeting in Orlando, Florida, where UCB will share additional insights into BIMZELX's impacts across various other immune-mediated inflammatory diseases.

The promising data about BIMZELX® supports its role as a leading treatment option for those afflicted with hidradenitis suppurativa, offering considerable hope for a better quality of life for patients grappling with this chronic condition.

Conclusion

As we await further detailed findings from the ongoing trials and studies, the current results highlight BIMZELX® as a critical advancement in the treatment landscape for hidradenitis suppurativa. With its dual-action mechanism, it stands out as a transformative option for patients, paving the way for improved management of this debilitating disease.